Country: Canada
Language: English
Source: Health Canada
DARUNAVIR (DARUNAVIR ETHANOLATE)
JANSSEN INC
J05AE10
DARUNAVIR
400MG
TABLET
DARUNAVIR (DARUNAVIR ETHANOLATE) 400MG
ORAL
60
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0151656002; AHFS:
CANCELLED POST MARKET
2016-09-01
_Approved Product Monograph 1.doc _ _Page 1 of 90 _ PRODUCT MONOGRAPH PR PREZISTA ® darunavir tablets 75 mg, 150 mg, 400 mg, 600 mg, 800 mg darunavir oral suspension 100 mg/mL (as darunavir ethanolate) Human Immunodeficiency Virus (HIV) Protease Inhibitor Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.com/canada Date of Preparation: July 27, 2006 Date of Revision: August 15, 2016 Submission Control No: 188263 © 2016 Janssen Inc. All trademarks used under license. _Approved Product Monograph 1.doc _ _Page 2 of 90 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ......................................................................................................... 10 DRUG INTERACTIONS ......................................................................................................... 22 DOSAGE AND ADMINISTRATION ..................................................................................... 38 OVERDOSAGE ....................................................................................................................... 41 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 42 STORAGE AND STABILITY ................................................................................................. 45 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 46 PART II: SCIENTIFIC INFORMATION .......................................................... Read the complete document